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Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS) and proteus syndrome are disorders known as
PTEN hamartoma tumour syndrome (PHTS), that can show remarkable clinical overlap and are all caused by
germline PTEN mutations.
We here present two families, one affected by CS and the other affected by BRRS, both carriers of specific
pathogenetic missense mutation in exon 5 of PTEN gene, within the catalitic domain. Both PHTS families exhibited
extremely variable phenotypes, showing inter- and intra- familial variability. One of the two characterised mutations,
the c.320A- > T; p.107Asp- > Val, identified in the CS family, was not previously described in the literature.
Furthermore, the BRRS family, carrier of the c.406 T- > C; p.136Cys- > Arg mutation, shows a substantial alteration of
PTEN protein expression that well correlates with intra-familial phenotypic variability.
Finally, we describe an apparently sporadic case of an 80-year-old man, with a very low level of PTEN mRNA and
protein expression, both in healthy and tumour colon mucosa, associated with a very atypical phenotype. He
developed a metastatic colorectal carcinoma, macrocephaly and pheochromocytoma.
According to literature data, our observations confirm that PTEN mutations of catalytic domain can cause different
syndromes. We suggest that PTEN expression could represent one of the mechanisms involved in the remarkable
heterogeneity of the clinical PHTS manifestations within affected families. Furthermore, constitutive strong decrease
of PTEN expression in colon normal mucosa could be associated with late onset of colorectal cancer.
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(BRRS), Sporadic pheochromocytoma, Macrocephaly, PTEN tumour suppressor gene, HaploinsufficiencyBackground
PTEN hamartoma tumour syndrome (PHTS) is the
term recently adopted to describe Cowden syndrome
(CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS),
Proteus syndrome (PS), and Proteus-like syndrome. All
these disorders are caused by mutations in the PTEN
gene and are characterised by extraintestinal manifesta-
tions in addition to intestinal polyposis. PHTS is inherited* Correspondence: marina.derosa@unina.it
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reproduction in any medium, provided the orin an autosomal dominant manner, and is likely to be
underdiagnosed because of its phenotypic variability,
its incomplete penetrance, and also due to the occurrence
of many of its component features in the general
population [1].
CS is a rare multiple hamartoma syndrome with a
reported incidence of 1 in 200,000 individuals. This
syndrome is characterised by macrocephaly, mucocutane-
ous lesions (such as facial trichilemmoma), acral keratosis,
glycogenic acanthosis of the esophagus and papillomatous
papules. It is also associated with thyroid, breast and
endometrial manifestations, including cancer in all of
these areas [2]. Renal cancer has also been associatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in CS is still unclear. The BRRS is a congenital disorder
characterised by macrocephaly, intestinal hamartomatous
polyposis, lipomas, and pigmentated macules of the gland
penis; individuals with BRRS should be considered at risk
for malignancy, as it is for CS. About 85% of individuals
who meet the diagnostic criteria for CS and 65% of indi-
viduals with a clinical diagnosis of BRRS have a detectable
PTEN gene mutation [2,3]. Recently, we reported two af-
fected subjects, with clinical manifestations of PHTS, asso-
ciated with alteration of PTEN mRNA expression, without
point mutations within the coding region of the gene [4].
Since the most serious consequences of PHTS relate
to the increased risk of breast, thyroid, endometrial
and renal cancers, cancer surveillance is of paramount
importance in the management of individuals with a
PTEN mutation [2,3].
PTEN is a 9-exon tumour suppressor gene that encodes
for a 403 amino acids protein. It acts as a lipid phosphatase
that negatively regulate the PI3K/AKT/mTOR pathway
[5,6]. Almost 100 different germ-line mutations of PTEN
have been reported to date encompassing point, nonsense,
frame shift, splice site, missense and deletion/insertion
mutations. Most mutations occur in exon 5, but muta-
tions in all other exons, except the first, have also been
described [2].
Here we present two families, respectively affected
by CS and BRRS syndrome, both carriers of a missense
mutation in the catalytic domain of PTEN protein. Be-
cause of great phenotypic variability observed in family 2,
we performed PTEN protein quantification on peripheral
blood cells collected from all subjects of this family.
Western blot assay shows that PTEN protein expression
well correlates with severity of disease in this family.
Furthermore, we describe a sporadic case showing a
very low level of PTEN mRNA and protein expression,
both in the healthy and cancer colon mucosa, associated
with a very atypical phenotype.
Methods
Patients
Samples from all subjects who participated in the study
were collected after being granted authorisation from the
“Comitato etico per le attività Biomediche – Carlo Romano”
of the University of Naples Federico II, with protocol
number 120/10. Once the authorisation has been obtained
the study has received ethical approval, and participants’
informed and written consent has been obtained.
Case presentation
Case 1
The proband 1 was a man affected by Bannayan-
Riley-Ruvalcaba syndrome, whose clinical diagnosis was
made at the age of 20 years after an endoscopicexamination that revealed multiple intestinal hamar-
tomatous gastric polyps and duodenal ulcers.
As previously described [4], polyps found in this family
were hamartomas with glandular structures, muscle fibers
and also ganglioneuromatosis elements.
At the age of 38 years he developed a colon carcinoma.
He also showed macrocephaly with a square cranium
and a broad asymmetry of the cerebral hemispheres,
glycogenic acanthosis of the esophagus, penis macules,
keratosis of the hands and feet and ilo-splenic arterio-
venous malformation. The proband's father and brother
both showed penis macules; they died of colon cancer at
the ages of 80 and 49 years, respectively. As we previously
described [4], molecular diagnosis revealed the presence
of a missense mutation of PTEN exon 5, the c.406 T- > C;
p.136Cys > Arg.
His 32 years old daughter was carrier of the same
PTEN mutation, but she had no clear sign of the disease.
She underwent to colonoscopy that revealed the presence
of few fundic and duodenal polyps; she was also affected
by Hashimoto disease. Secondary amenorrhea occurred
at the age of 25 and she showed genitalis macules. Her
31-year-old cousin, also carrier of the pathogenetic
mutation, developed only one intestinal polyp.Case 2
The proband 2 was a man affected by Cowden syndrome.
He showed glycogenic acanthosis of the esophagus,
keratosis of the hands and of the feet and only polyps
characterised of Juvenile polyps. He later developed a
metastatic and locally advanced rectal cancer and
hamartomatous small stomach polyps. His daughter,
also carrier of the same PTEN mutation, developed few
hamartomatous colon polyps since the age of 10. She was
also affected by Hashimoto disease and arteriovenous
malformation and showed small facial keratosis.Case 3
In case 3, an 80-year-hold man (proband 3), developed a
metastatic colorectal carcinoma. He showed macrocephaly
and had previously developed a pheochromocytoma.
No other endocrine tumours were referred in their
first-degree relatives.Molecular analysis of the PTEN gene
Molecular analysis of PTEN gene (reported in Methods
section, Additional file 1) was performed using a com-
bination of PCR, RT-PCR, sequencing of amplified frag-
ment, dHPLC, computational analysis of mutations with
PolyPhen-2 software and SIFT software, Real-Time PCR
and Western blot.
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We performed mutational analysis of the PTEN gene,
setting-up a combination of RT-PCR reaction of the whole
cDNA, PCR of genomic region and sequencing of the
amplified fragments.
As we previously reported [4], proband of family 1,
affected by BRRS, had a missense mutation named
c.406 T- > C, p.136Cys- > Arg in exon 5 of PTEN gene
(Figure 1A). This mutation, already described in the
literature, results in amino acid substitution of cysteine
into an arginine residue at position 136 [7,8].Figure 1 PTEN exon 5 gene mutations identified in PHTS patients. A a
performed on amplified fragments from gDNA of the patients 1 and 2. Rep
mutations: c.406 T- > C; p.136Cys- > Arg and c.320A- > T; p.107Asp- > Val. Th
C and D) In sylico analysis of identified mutations. Graphical representations
c.406 T- > C; p.136Cys- > Arg and c.320A- > T; p.107Asp- > Val.As shown in Figure 1B, proband of family 2, affected by
CS, had a missense mutation, the c.320A- > T; p.107Asp- >
Val mutation, in exon 5 of PTEN gene. This mutation,
not previously described in literature, results in amino
acid substitution of the asparagine residue into a valine
at position 107. These two mutations were predicted to
be probably damaging, under computational analysis
using PolyPhen-2 software, with a same score of 1.000
(Figures 1C and 1D) and SIFT software with a score of 0.
and 0.01, respectively and with a same Median Information
Content of 2.52.nd B) Sequence analysis PTEN exon 5 region. Sequence analysis was
orted here are the electropherograms around the identified
e specific mutated nucleotide is showed within the black box.
of PolyPhen-2 computational analysis obtained for mutations
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formed within family 1 and were analysed two daughters
and two nephews of the proband. Two of them (subject
III-2 and III-4) were carrier of the mutation, as indicated in
Figures 2A and 2B. Because of great phenotypic variability
observed in family 2, we performed PTEN protein quantifi-
cation on peripheral blood cells collected from all subjects
of this family. Western blot assay shows that PTEN protein
expression well correlates with severity of disease in
this family. Indeed, the proband, subject II-3 of pedi-
gree in Figure 2A, that exhibited the more severe
phenotype among all relatives, also shows the lowest
level of PTEN protein expression (Figure 3A). As de-
scribed in “case presentation” section, he developed aFigure 2 Molecular analysis of c.406 T- > C; p.136Cys- > Arg mutation
mutation positive subjects; MUT-: mutation negative subjects. The arrow in
daughter; III-2: affected nephew; III-1: unaffected nephew. B) dHPLC analysis
amplified fragment within members of family 1.colon carcinoma, showed macrocephaly with a square cra-
nium and a broad asymmetry of the cerebral hemispheres,
glycogenic acanthosis of the esophagus, penis macules,
keratosis of the hands and feet and ilo-splenic arterioven-
ous malformation. Instead, his affected daughter and his
nephew, respectively subjects III-4 and III-2 of Figure 2A,
both carrier of same mutation, did not show unambiguous
signs of the disease. Subject III-4, who had a negative col-
onoscopy, was affected by Hashimoto disease and second-
ary amenorrhea arising around 25 years. She referred
increase of the body weight. Her cousin, subject III-2 of
pedigree in Figure 2A, presented only one intestinal polyp.
This result suggests that PTEN gene dosage could play a
role on phenotypic variability observed in this family.within family 1. A) Pedigree of family 1. N.A.: not analysed; MUT+:
dicates proband 1 (II-3); III-4: affected daughter; III-3: unaffected
within family 1. dHPLC chromatogram obtained for PTEN exon 5 PCR
Figure 3 PTEN protein analysis. Representative image of three repeated experiments qualitatively similar. A) Western blot assay of PTEN
performed on protein extracts from peripheral blood cells. The amounts of PTEN and β-actin were measured by Western blot. II-3, III-4, III-3, III-2, III-1:
patients-numbering corresponds to that adopted in the shown pedigree. B) Histogram showing optical density of PTEN protein normalized versus
actin protein: Density of the electrophoretic band was obtained with ImageJ software. Relative quantification of PTEN protein normalized versus
actin protein was calculated using sample III-3 as calibrator. C) Western blot assay of PTEN performed on protein extracts from colon mucosa. N2:
healthy colon mucosa and P2: amartomatous polyp of proband’s daughter described in case 2; N3: healthy colon mucosa and T3: colorectal
carcinoma of proband 3; C: healthy colon mucosa. D) Histogram showing optical density of PTEN protein normalized versus actin protein: Density of
the electrophoretic band was obtained with ImageJ software. Relative quantification of PTEN protein normalized versus actin protein was
calculated using sample N-2 as calibrator.
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lected from healthy colon mucosa (N2) and hamartomatous
polyp (P2) of proband’s daughter described in case 2 and
from healthy colon mucosa (N3) and colorectal carcinoma
(T3) of proband 3.
As showed in Figure 3B, PTEN protein expression was
only slightly lower in the hamartomatous polyp compared
to its matched normal mucosa (N2 and P2). Instead,
we observed a very low level of PTEN expression both
in healthy and colorectal cancer tissue collected from
proband 3, compared to healthy colorectal mucosa of
unaffected subject (C). Moreover, real time RT-PCR
quantification of PTEN messenger on normal and colo-
rectal mucosa from proband 3, did not give any signal
(data not shown). Overall, these observations suggest
that proband 3 could be carrier of a constitutive down-
regulation of PTEN mRNA and protein. We can not
exclude that germ-line alterations in other genes, such as
SDHB, SDHC, SDHD,VHL, or RET, reported to be altered
in patients with apparently sporadic pheochromocytoma
[9,10], could be responsible for PTEN somatic inactivation
observed in this patient at the level of healthy colorectal
mucosa. Unfortunately, he died before we could further
analyse genomic DNA extracted from his peripheral blood
cells.
It has been demonstrated that PTEN is a bona fide
haploinsufficient tumour suppressor gene. A continuum
working model, in which subtle variations in the expression
of tumour suppressor genes may have a profound impact
on tumour susceptibility and progression, has been
proposed [11]. In agreement with Alimenti et al. [11], our
observations suggest a contribution of PTEN gene dosage
on phenotypic variability of PHTS patients. In this
context, quantitative PTEN expression analysis should
be extended to point-mutations molecular screening to
obtain a more precise interpretation of molecular diagnosis
and a better characterization of PHTS patients.
Indeed, PHTS disorders are likely to be underdiagnosed
because of their phenotypic variability and their incom-
plete penetrance [12,13]. However, we can not exclude, as
described for other syndromes, that different mechanisms,
such as alternative splicing mechanisms [14,15] or allelic
variants of modifier genes, could contribute to the observed
phenotypic variability [16].
Interestingly, mutants of PTEN that maintain partial
function may have a selective advantage over mutants that
confer a complete loss of function, because complete loss
of PTEN induces the activation of a p53-dependent cellular
senescence response [17,18]. According with this hypoth-
esis, proband number 3 developed colorectal cancer at the
age of 80 years. In our knowledge, this is the first case of
CRC patient showing a constitutive strong decrease of
PTEN expression in healthy colon mucosa, associated with
a colorectal cancer late onset and pheochromocytoma.Conclusion
In agreement to recent models of PTEN function de-
scribed by Salmena et al. [19], we suggest that phenotypes
showed in the cases here reported reflect a continuum of
functional PTEN loss, suggesting a role for PTEN quanti-
tative regulation on phenotypic variability, either in PHTS
families or in apparently sporadic colorectal cancer. Wide
population studies will be necessary to better clarify the
role of germ-line and/or somatic PTEN gene dosage on
phenotypic heterogeneity of PHTS patients and apparently
sporadic colorectal cancer patients.
Additional file
Additional file 1: Molecular analysis of the PTEN gene [20].
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